The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare, preventative treatments, early diagnosis, reducing patient recovery times and improving outcomes, and growing importance of technologies such as machine learning, augmented reality, 5G and digitalization. In the last three years alone, there have been over 710,000 patents filed and granted in the medical devices industry, according to GlobalData’s report on Innovation in medical: intranasal drug delivery. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
30+ innovations will shape the medical devices industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the medical devices industry using innovation intensity models built on over 155,000 patents, there are 30+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, ultrasonic nebulizers and intra-oral 3D imaging are disruptive technologies that are in the early stages of application and should be tracked closely. Intraocular pressure monitoring, automated diabetes management, and tissue repair implants are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas is CPR assistance devices, which is now well established in the industry.
Innovation S-curve for the medical devices industry
Intranasal drug delivery is a key innovation area in medical devices
Intranasal drug delivery is a non-invasive technique for administering medication via the nasal passage. It involves the introduction of medication in various forms, such as aerosols, gels, or dry powders, through the nasal cavity, facilitating rapid absorption into the bloodstream through the nasal mucosa. This approach is particularly beneficial for drugs requiring swift action.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established medical devices companies, and up-and-coming start-ups engaged in the development and application of intranasal drug delivery.
Key players in intranasal drug delivery – a disruptive innovation in the medical devices industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to custom intranasal drug delivery
Source: GlobalData Patent Analytics
Syqe Medical and Grupo Ferrer Internacional are two of the leading patent filers in intranasal drug delivery devices. Some other key patent filers include Insmed, Eli Lilly, and Toko Pharmaceutical Industries.
In terms of application diversity, Enviroscent leads the pack, while AYR and Koninklijke Philips stood in the second and third positions, respectively. By means of geographic reach, Insmed held the top position, followed by OptiNose and AbbVie.
Intranasal delivery of drugs directly to the central nervous system is being preferred as it circumvents the blood brain barrier. Intranasal drug delivery devices are expected to see increased usage in the coming years, due to their efficiency in facilitating quick and precise administration of drugs that lead to lower side effects and an increased patient adherence. Using advanced approaches such as nanomedicine and nanocarriers, intranasal drug delivery will represent an opportunity to treat currently incurable diseases.
To further understand the key themes and technologies disrupting the medical devices industry, access GlobalData’s latest thematic research report on Medical Devices.